Bacterial vaginosis: review of treatment options and potential clinical indications for therapy
- PMID: 10028110
- DOI: 10.1086/514725
Bacterial vaginosis: review of treatment options and potential clinical indications for therapy
Abstract
We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic disease, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.
Similar articles
-
Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole.Obstet Gynecol. 1992 Jun;79(6):1020-3. Obstet Gynecol. 1992. PMID: 1579299 Clinical Trial.
-
Bacterial vaginosis: review of treatment options and potential clinical indications for therapy.Clin Infect Dis. 1995 Apr;20 Suppl 1:S72-9. doi: 10.1093/clinids/20.supplement_1.s72. Clin Infect Dis. 1995. PMID: 7795111 Review.
-
Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data.Clin Infect Dis. 2002 Oct 15;35(Suppl 2):S152-72. doi: 10.1086/342103. Clin Infect Dis. 2002. PMID: 12353202
-
Treatment options for bacterial vaginosis in patients at high risk of preterm labor and premature rupture of membranes.J Obstet Gynaecol Res. 2007 Dec;33(6):781-7. doi: 10.1111/j.1447-0756.2007.00656.x. J Obstet Gynaecol Res. 2007. PMID: 18001442 Clinical Trial.
-
[Current treatment of bacterial vaginosis].Akush Ginekol (Sofiia). 1999;38(1):76-8. Akush Ginekol (Sofiia). 1999. PMID: 11965732 Review. Bulgarian.
Cited by
-
BASIC study: is intravaginal boric acid non-inferior to metronidazole in symptomatic bacterial vaginosis? Study protocol for a randomized controlled trial.Trials. 2015 Jul 26;16:315. doi: 10.1186/s13063-015-0852-5. Trials. 2015. PMID: 26210791 Free PMC article. Clinical Trial.
-
An exploratory pilot study evaluating the supplementation of standard antibiotic therapy with probiotic lactobacilli in south African women with bacterial vaginosis.BMC Infect Dis. 2019 Sep 18;19(1):824. doi: 10.1186/s12879-019-4425-1. BMC Infect Dis. 2019. PMID: 31533663 Free PMC article. Clinical Trial.
-
Tinidazole in the treatment of bacterial vaginosis.Int J Womens Health. 2010 Aug 9;1:59-65. doi: 10.2147/ijwh.s4455. Int J Womens Health. 2010. PMID: 21072275 Free PMC article.
-
Low prevalence of cervical infections in women with vaginal discharge in west Africa: implications for syndromic management.Sex Transm Infect. 2004 Jun;80(3):230-5. doi: 10.1136/sti.2003.007534. Sex Transm Infect. 2004. PMID: 15170011 Free PMC article. Clinical Trial.
-
PROJECT PREVENT: a randomized controlled trial of preoperative vaginal metronidazole to decrease patient issues and infections after hysterectomy.BMJ Surg Interv Health Technol. 2024 Apr 4;6(1):e000241. doi: 10.1136/bmjsit-2023-000241. eCollection 2024. BMJ Surg Interv Health Technol. 2024. PMID: 38596254 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical